Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | FABP4 | P15090 | 7/20 | 0.53 |
| ▸ | FABP5 | Q01469 | 7/20 | 0.53 |
| ▸ | FABP3 | P05413 | 6/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14916445 | 0.84 | FABP4 (0.65) | ADORA2AKDM4ERXFP1HPGDALDH1A1 | |
| SCHEMBL14917285 | 0.83 | FABP4 (0.64) | ADORA2AKDM4ERXFP1HPGDALDH1A1 | |
| SCHEMBL14932830 | 0.80 | ADORA2A (0.42) | ADORA2AKDM4ERXFP1HPGDALDH1A1 | |
| SCHEMBL14917385 | 0.76 | FABP4 (0.75) | FABP4FABP5FABP3CYP2C9CYP2D6 | |
| SCHEMBL14927262 | 0.76 | FABP4 (0.51) | ADORA2AFABP4FABP5FABP3CYP2C9 | |
| SCHEMBL28112739 | 0.72 | FABP4 (0.70) | ADORA2AKDM4ERXFP1HPGDALDH1A1 | |
| SCHEMBL14917256 | 0.72 | ADORA2A (0.56) | ADORA2AKDM4ERXFP1HPGDALDH1A1 | |
| SCHEMBL26632973 | 0.71 | ADORA2A (0.84) | ADORA2AKDM4ERXFP1HPGDALDH1A1 | |
| SCHEMBL31215450 | 0.71 | ADORA2A (0.71) | ADORA2AKDM4ERXFP1HPGDALDH1A1 | |
| SCHEMBL26632970 | 0.71 | ADORA2A (0.71) | ADORA2AKDM4ERXFP1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809599-B2 | Aryl-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809599-B2 | Aryl-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809599-B2 | Aryl-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-11-07 | — | — | US | disclosed |
| EP-2773619-B1 | NEW ARYL-QUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-11-16 | — | — | EP | disclosed |
| EP-2773619-B1 | NEW ARYL-QUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-11-16 | — | — | EP | disclosed |
| US-20160060270-A1 | New Aryl-Quinoline Derivatives | HOFFMANN-LA ROCHE INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160060270-A1 | New Aryl-Quinoline Derivatives | HOFFMANN-LA ROCHE INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160060270-A1 | New Aryl-Quinoline Derivatives | HOFFMANN-LA ROCHE INC. | 2016-03-03 | — | — | US | disclosed |
| US-9199938-B2 | Aryl-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199938-B2 | Aryl-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199938-B2 | Aryl-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2773619-A1 | NEW ARYL-QUINOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013064465-A1 | NEW ARYL-QUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013064465-A1 | NEW ARYL-QUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116234-A1 | ARYL-QUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116234-A1 | ARYL-QUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116234-A1 | ARYL-QUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116234-A1 | ARYL-QUINOLINE DERIVATIVES | FABP1, FABP4, FABP5 | ADORA2A 2506/4885KDM4E 2685/4885RXFP1 193/4885 |
| US-20160060270-A1 | New Aryl-Quinoline Derivatives | FABP1, FABP4, FABP5 | ADORA2A 2406/4885KDM4E 2496/4885RXFP1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.